Targeting hypoxic cancer stem cells (CSCs) with Doxycycline : implications for optimizing anti-angiogenic therapy

De Francesco, EM, Maggiolini, M, Tanowitz, HB, Sotgia, F and Lisanti, MP 2017, 'Targeting hypoxic cancer stem cells (CSCs) with Doxycycline : implications for optimizing anti-angiogenic therapy' , Oncotarget .

[img]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (5MB) | Preview
[img] PDF - Accepted Version
Restricted to Repository staff only

Download (2MB) | Request a copy

Abstract

Here, we report new mechanistic insight into how chronic hypoxia increases ‘stemness’ in cancer cells. Using chemical inhibitors, we provide direct experimental evidence that ROS production and mitochondrial biogenesis are both required for the hypoxia-induced propagation of CSCs. More specifically, we show that hypoxic CSCs can be effectively targeted with i) simple mitochondrial anti-oxidants (Mito-TEMPO) and/or ii) inhibitors of mitochondrial biogenesis (Doxycycline). In this context, we discuss the idea that mitochondrial biogenesis itself may be a primary driver of “stemness” in hypoxic cancer cells, with metabolic links to fatty acid oxidation (FAO). As Doxycycline is an FDA-approved drug, we propose that it could be re-purposed to target hypoxic CSCs, either alone or in combination with chemotherapy, i.e., Paclitaxel. For example, we demonstrate that Doxycycline effectively targets the sub-population of hypoxia-induced CSCs that are Paclitaxel-resistant, overcoming hypoxia-induced drug-resistance. Finally, anti-angiogenic therapy often induces tumor hypoxia, allowing CSCs to survive and propagate, ultimately driving tumor progression. Therefore, we suggest that Doxycycline could be used in combination with anti-angiogenic agents, to actively prevent or minimize hypoxia-induced treatment failure. In direct support of this assertion, Paclitaxel is already known to behave as an angiogenesis inhibitor.

Item Type: Article
Schools: Schools > School of Environment and Life Sciences > Biomedical Research Centre
Journal or Publication Title: Oncotarget
Publisher: Impact Journals
ISSN: 1949-2553
Related URLs:
Depositing User: F Sotgia
Date Deposited: 12 Jul 2017 11:25
Last Modified: 11 Dec 2017 22:02
URI: http://usir.salford.ac.uk/id/eprint/42939

Actions (login required)

Edit record (repository staff only) Edit record (repository staff only)

Downloads

Downloads per month over past year